Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis

Akira Miyajima, Takeo Kosaka, Tomohiko Asano, Takako Asano, Kaori Seta, Toshiaki Kawai, Masamichi Hayakawa

Research output: Contribution to journalArticle

144 Citations (Scopus)

Abstract

Angiotensin II (AII) is a potent vasoconstrictor peptide from the reninangiotensin system in the kidney. The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis. We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis. Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 ± 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 ± 8.6; n = 13). Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.

Original languageEnglish
Pages (from-to)4176-4179
Number of pages4
JournalCancer Research
Volume62
Issue number15
Publication statusPublished - 2002 Aug 1
Externally publishedYes

Fingerprint

Angiotensin I
Kidney Neoplasms
Angiotensin II
Neoplasm Metastasis
Lung
Renal Cell Carcinoma
Neoplasms
Angiotensin Type 1 Receptor
Vasoconstrictor Agents
Vascular Endothelial Growth Factor A
Lung Neoplasms
Kidney
Peptides
Therapeutics
candesartan

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Miyajima, A., Kosaka, T., Asano, T., Asano, T., Seta, K., Kawai, T., & Hayakawa, M. (2002). Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Research, 62(15), 4176-4179.

Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. / Miyajima, Akira; Kosaka, Takeo; Asano, Tomohiko; Asano, Takako; Seta, Kaori; Kawai, Toshiaki; Hayakawa, Masamichi.

In: Cancer Research, Vol. 62, No. 15, 01.08.2002, p. 4176-4179.

Research output: Contribution to journalArticle

Miyajima, A, Kosaka, T, Asano, T, Asano, T, Seta, K, Kawai, T & Hayakawa, M 2002, 'Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis', Cancer Research, vol. 62, no. 15, pp. 4176-4179.
Miyajima, Akira ; Kosaka, Takeo ; Asano, Tomohiko ; Asano, Takako ; Seta, Kaori ; Kawai, Toshiaki ; Hayakawa, Masamichi. / Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. In: Cancer Research. 2002 ; Vol. 62, No. 15. pp. 4176-4179.
@article{dd5ff91072f646e4aa11efbcb73a35d2,
title = "Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis",
abstract = "Angiotensin II (AII) is a potent vasoconstrictor peptide from the reninangiotensin system in the kidney. The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis. We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis. Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 ± 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 ± 8.6; n = 13). Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.",
author = "Akira Miyajima and Takeo Kosaka and Tomohiko Asano and Takako Asano and Kaori Seta and Toshiaki Kawai and Masamichi Hayakawa",
year = "2002",
month = "8",
day = "1",
language = "English",
volume = "62",
pages = "4176--4179",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis

AU - Miyajima, Akira

AU - Kosaka, Takeo

AU - Asano, Tomohiko

AU - Asano, Takako

AU - Seta, Kaori

AU - Kawai, Toshiaki

AU - Hayakawa, Masamichi

PY - 2002/8/1

Y1 - 2002/8/1

N2 - Angiotensin II (AII) is a potent vasoconstrictor peptide from the reninangiotensin system in the kidney. The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis. We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis. Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 ± 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 ± 8.6; n = 13). Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.

AB - Angiotensin II (AII) is a potent vasoconstrictor peptide from the reninangiotensin system in the kidney. The AII type 1 receptor (AT1R) is reportedly expressed in several tumors including renal cell carcinoma, and AII is involved in tumor angiogenesis. We p.o. administered the long-acting AT1R antagonist, candesartan (10 mg/kg), to the 16 days mouse renal cancer lung metastasis model to test the preventive effects in tumor metastasis. Pulmonary metastases of renal cancer showed prominent AT1R expression in both mice and humans, and candesartan treatment dramatically prevented lung metastatic nodules (14.9 ± 1.8; P < 0.0001; n = 12) in mice along with the inhibition of neovascularization and vascular endothelial growth factor expression, compared with control metastatic mice (123.3 ± 8.6; n = 13). Candesartan is widely used clinically, so it seems to be a reasonable therapy for patients with lung metastases of renal cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0036681694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036681694&partnerID=8YFLogxK

M3 - Article

C2 - 12154013

AN - SCOPUS:0036681694

VL - 62

SP - 4176

EP - 4179

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -